How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,042 results for

Ketamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Anesthetic effects and body weight changes associated with ketamine-xylazine-lidocaine administered to CD-1 mice. (PubMed)

Anesthetic effects and body weight changes associated with ketamine-xylazine-lidocaine administered to CD-1 mice. Anesthesia for mice is commonly performed through the injection of parenteral agents via the intraperitoneal (IP) route. Variability in anesthetic sensitivities has been noted in mice resulting in inconsistencies in anesthetic depth and/or mortality. Anesthetic protocols that improve consistency and safety are needed. The objectives of this study were to assess the effects (...) of intraperitoneal (IP) ketamine (95 mg/kg) and xylazine (7 mg/kg) alone or combined with lidocaine at 4, 8, or 16 mg/kg on time to loss (LRR) and return (RRR) of righting reflex, duration of immobilization and loss of pedal withdrawal response (PWR), body weight and histopathology in CD-1 mice. In a prospective, randomized trial, 36 male CD-1 mice, 4-6 weeks of age were randomly assigned to 5 groups: saline (SA, n = 4); ketamine-xylazine (KX, n = 8); ketamine-xylazine-lidocaine 4 mg/kg (KXL4, n = 8); ketamine

Full Text available with Trip Pro

2017 PLoS ONE

82. Neuronal correlates of ketamine and walking induced gamma oscillations in the medial prefrontal cortex and mediodorsal thalamus. (PubMed)

Neuronal correlates of ketamine and walking induced gamma oscillations in the medial prefrontal cortex and mediodorsal thalamus. Alterations in the function of the medial prefrontal cortex (mPFC) and its major thalamic source of innervation, the mediodorsal (MD) thalamus, have been hypothesized to contribute to the symptoms of schizophrenia. The NMDAR antagonist ketamine, used to model schizophrenia, elicits a brain state resembling early stage schizophrenia characterized by cognitive deficits (...) and increases in cortical low gamma (40-70 Hz) power. Here we sought to determine how ketamine differentially affects spiking and gamma local field potential (LFP) activity in the rat mPFC and MD thalamus. Additionally, we investigated the ability of drugs targeting the dopamine D4 receptor (D4R) to modify the effects of ketamine on gamma activity as a measure of potential cognitive therapeutic efficacy. Rats were trained to walk on a treadmill to reduce confounds related to hyperactivity after ketamine

Full Text available with Trip Pro

2017 PLoS ONE

83. Ketamine-propofol (ketofol) for procedural sedation and analgesia in pediatric patients

Ketamine-propofol (ketofol) for procedural sedation and analgesia in pediatric patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

84. Ketamine for emergence agitation in children: a systematic review and meta-analysis with trial sequential analysis

Ketamine for emergence agitation in children: a systematic review and meta-analysis with trial sequential analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

85. The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis

The effect of ketamine on psychopathology and implications for understanding schizophrenia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

86. Therapeutic and recreational use of ketamine and mental health outcomes: a systematic review

Therapeutic and recreational use of ketamine and mental health outcomes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

87. Ketamine versus fentanyl for trauma analgesia in prehospital care: a systematic review

Ketamine versus fentanyl for trauma analgesia in prehospital care: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

88. Ketamine induces neuroplasticity in patients with major depressive disorder: a systematic review

Ketamine induces neuroplasticity in patients with major depressive disorder: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

89. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment (PubMed)

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment Prefrontal global brain connectivity with global signal regression (GBCr) was proposed as a robust biomarker of depression, and was associated with ketamine's mechanism of action. Here, we investigated prefrontal GBCr in treatment-resistant depression (TRD) at baseline and following treatment. Then, we conducted a set of pharmacological challenges in healthy subjects to investigate (...) the glutamate neurotransmission correlates of GBCr.In study A, we used functional magnetic resonance imaging (fMRI) to compare GBCr between 22 TRD and 29 healthy control. Then, we examined the effects of ketamine and midazolam on GBCr in TRD patients 24h post-treatment. In study B, we acquired repeated fMRI in 18 healthy subjects to determine the effects of lamotrigine (a glutamate release inhibitor), ketamine, and lamotrigine-by-ketamine interaction.In study A, TRD patients showed significant reduction

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

90. Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? (PubMed)

Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? 29560906 2019 02 27 2019 02 27 2451-9030 2 7 2017 10 Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics? 549-551 S2451-9022(17)30146-5 10.1016/j.bpsc.2017.08.006 Nugent Allison C AC Experimental Therapeutics and Pathophysiology Branch

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

91. The use of a sub-dissociative dose of ketamine with opioids compared to opioids alone in the management of severe pain in adults in emergency settings: proposal for systematic review

The use of a sub-dissociative dose of ketamine with opioids compared to opioids alone in the management of severe pain in adults in emergency settings: proposal for systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

92. Subcutaneous ketamine in depression: a systematic review

Subcutaneous ketamine in depression: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

93. A systematic review and meta-analysis of ketamine dependence

A systematic review and meta-analysis of ketamine dependence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

94. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.

The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. Since the discovery of antidepressants, new treatments have emerged with fewer side effects but no greater efficacy. Glycogen synthase kinase 3 β (GSK-3β), a kinase known for its activity on glycogen synthesis, has in the last few years raised growing interest in biological psychiatry. Several efficient treatments in major depression have (...) -arrestin/AKT, and with the rapid antidepressant effect of ketamine via p70S6K.Our review focuses on mechanisms whereby the GSK-3β pathway has a part in the antidepressant effect of lithium and ketamine. This article highlights the importance of translational research from cell and animal models to the clinical setting in order to develop innovative therapeutic targets.Copyright © 2016 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

2017 L'Encephale

95. Ketamine in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials

Ketamine in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

96. Ketamine for prehospital pain management in military trauma

Ketamine for prehospital pain management in military trauma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

97. The effects of ketamine/propofol admixture on peri-induction hemodynamics: a systematic review and meta-analysis

The effects of ketamine/propofol admixture on peri-induction hemodynamics: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

98. Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department (PubMed)

Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department We compare the frequency of airway and respiratory adverse events leading to an intervention between propofol with 1:1 and 4:1 mixtures of propofol and ketamine (ketofol).We performed a randomized, double-blinded trial in which emergency department adults undergoing deep sedation received propofol, 1:1 propofol and ketamine, or 4:1 (...) propofol and ketamine. Our primary outcome was the frequency of airway and respiratory adverse events leading to an intervention. Other outcomes included sedation depth, efficacy, procedure and recovery time, patient satisfaction, pain, and procedural recall.Two hundred seventy-one subjects completed the trial, 90 receiving propofol, 85 receiving 1:1 propofol and ketamine, and 96 receiving 4:1 propofol and ketamine. Airway or respiratory adverse events leading to an intervention were similar between

2014 EvidenceUpdates Controlled trial quality: predicted high

99. Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children?

Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children? Systematic Review Snapshot TAKE-HOME MESSAGE Limited data from a single randomized controlled trial do not support the routine use of ketamine for children with acute asthma exacerbations that are unresponsive to initial aerosolized b 2 -agonist or steroids. Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children? EBEM Commentators Randolph P. Maddox, MD Rawle A. Seupaul, MD Department (...) of Emergency Medicine University of Arkansas for Medical Sciences Little Rock, AR Results Estimated bene?t of ketamine compared to placebo for children with acute asthma exacerbation that fail standard therapy based on a single trial (N¼68). Time Pulmonary Index Score (Mean Difference) 95% Con?dence Interval 2 h 0.40 (–0.4 to 1.3) The search identi?ed 5 potential studies; only 1 trial 2 met inclusion criteria so a meta-analysis could not be performed. This trial was appro- priately powered to detect

2013 Annals of Emergency Medicine Systematic Review Snapshots

100. Intravenous Ketamine for the Treatment of Pain Syndromes

Intravenous Ketamine for the Treatment of Pain Syndromes TITLE: Intravenous Ketamine for the Treatment of Pain Syndromes: Clinical Effectiveness DATE: 07 June 2013 RESEARCH QUESTIONS 1. What is the clinical effectiveness of intravenous (IV) ketamine for the treatment of recalcitrant chronic regional pain syndrome? 2. What is the clinical effectiveness of IV ketamine for the treatment of fibromyalgia? 3. What is the clinical effectiveness of IV ketamine for the treatment of reflex sympathetic (...) dystrophy? KEY MESSAGE One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness of IV ketamine for the treatment of fibromyalgia or reflex sympathetic dystrophy. METHODS

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>